Cerecin

About

Cerecin Inc. is a clinical-stage biotechnology company based in Denver, Colorado, with additional offices in Singapore, Australia, and South Korea. Founded in 2001, the company focuses on brain health and neurology, developing innovative therapeutics that target the metabolic aspects of central nervous system diseases. Cerecin has raised approximately $233.9 million through multiple funding rounds and collaborates with major partners like Nestlé S.A. and Wilmar International Limited. The company offers a range of products, including pharmaceuticals, medical foods, and diagnostics aimed at conditions such as Alzheimer's disease, infantile spasms, and migraines. Notable developments include CER-0001, an investigational oral drug designed to induce ketosis for treating metabolic deficits in the brain. Cerecin is advancing its pipeline through strategic acquisitions and partnerships, emphasizing research and development in neurometabolism and neurotherapeutics. The leadership team comprises experienced professionals dedicated to driving innovation in brain health solutions.